Alzheimer’s drug lecanemab may soon get full FDA approval. Who will get access? : Shots
[ad_1] In patients with Alzheimer’s disease, a substance called beta-amyloid can form toxic clumps in between neurons. Drugs like lecanemab are designed to remove amyloid-beta from the brain. National Institute on Aging, National Institutes of Health. hide caption toggle caption National Institute on Aging, National Institutes of Health. In patients with Alzheimer’s disease, a substance…
